Exagen Inc. (XGN)
USD 4.6
(7.98%)
USD 4.6
(7.98%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -22.83 Million USD | 43.67% |
| 2022 | -40.54 Million USD | -68.47% |
| 2021 | -24.06 Million USD | -58.49% |
| 2020 | -15.18 Million USD | -63.3% |
| 2019 | -9.29 Million USD | -90.55% |
| 2018 | -4.88 Million USD | 37.72% |
| 2017 | -7.83 Million USD | 0.0% |
| 2015 | -10.38 Million USD | 10.11% |
| 2014 | -11.55 Million USD | -26.38% |
| 2013 | -9.14 Million USD | -33.96% |
| 2012 | -6.82 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -2.58 Million USD | 13.85% |
| 2024 Q1 | -3 Million USD | 41.66% |
| 2023 Q1 | -7.7 Million USD | 14.23% |
| 2023 Q2 | -4.91 Million USD | 36.22% |
| 2023 Q4 | -5.14 Million USD | -1.54% |
| 2023 Q3 | -5.06 Million USD | -3.13% |
| 2023 FY | -22.83 Million USD | 43.67% |
| 2022 Q3 | -7.81 Million USD | 38.49% |
| 2022 Q4 | -8.98 Million USD | -14.94% |
| 2022 FY | -40.54 Million USD | -68.47% |
| 2022 Q1 | -9.67 Million USD | -55.14% |
| 2022 Q2 | -12.7 Million USD | -31.29% |
| 2021 Q4 | -6.23 Million USD | 4.07% |
| 2021 Q3 | -6.5 Million USD | -13.27% |
| 2021 Q2 | -5.74 Million USD | -3.14% |
| 2021 FY | -24.06 Million USD | -58.49% |
| 2021 Q1 | -5.56 Million USD | -101.63% |
| 2020 Q3 | -3.78 Million USD | -10.8% |
| 2020 FY | -15.18 Million USD | -63.3% |
| 2020 Q2 | -3.41 Million USD | 34.55% |
| 2020 Q4 | -2.76 Million USD | 27.07% |
| 2020 Q1 | -5.22 Million USD | -82.68% |
| 2019 Q3 | -2.15 Million USD | 10.5% |
| 2019 Q2 | -2.41 Million USD | -28.6% |
| 2019 Q1 | -1.87 Million USD | -1141.06% |
| 2019 FY | -9.29 Million USD | -90.55% |
| 2019 Q4 | -2.85 Million USD | -32.5% |
| 2018 Q3 | -1.13 Million USD | 22.82% |
| 2018 Q4 | -151 Thousand USD | 86.67% |
| 2018 FY | -4.88 Million USD | 37.72% |
| 2018 Q2 | -1.46 Million USD | 31.02% |
| 2018 Q1 | -2.12 Million USD | 0.0% |
| 2017 FY | -7.83 Million USD | 0.0% |
| 2015 Q2 | -2.65 Million USD | -8.77% |
| 2015 Q4 | -2.55 Million USD | 6.72% |
| 2015 FY | -10.38 Million USD | 10.11% |
| 2015 Q1 | -2.44 Million USD | -34.49% |
| 2015 Q3 | -2.73 Million USD | -3.13% |
| 2014 Q1 | -3.19 Million USD | -19.53% |
| 2014 Q4 | -1.81 Million USD | 45.13% |
| 2014 Q3 | -3.3 Million USD | -2.16% |
| 2014 Q2 | -3.23 Million USD | -1.35% |
| 2014 FY | -11.55 Million USD | -26.38% |
| 2013 Q1 | -1.9 Million USD | 0.0% |
| 2013 FY | -9.14 Million USD | -33.96% |
| 2013 Q3 | -2.07 Million USD | -11.54% |
| 2013 Q2 | -1.86 Million USD | 2.41% |
| 2013 Q4 | -2.67 Million USD | -28.63% |
| 2012 FY | -6.82 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aspira Women's Health Inc. | -18.85 Million USD | -21.138% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -186.421% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | -122.081% |
| Standard BioTools Inc. | -76.6 Million USD | 70.187% |
| Inotiv, Inc. | -81.46 Million USD | 71.965% |
| Prenetics Global Limited | -52.51 Million USD | 56.512% |
| Neuronetics, Inc. | -30.55 Million USD | 25.257% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -425.472% |
| Castle Biosciences, Inc. | -67.97 Million USD | 66.405% |
| Psychemedics Corporation | -2.92 Million USD | -681.821% |
| RadNet, Inc. | 98.69 Million USD | 123.138% |
| Exact Sciences Corporation | -215.01 Million USD | 89.379% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 102.082% |
| iSpecimen Inc. | -11.16 Million USD | -104.461% |
| OpGen, Inc. | -15.68 Million USD | -45.565% |
| Bionano Genomics, Inc. | -215.24 Million USD | 89.39% |
| CareDx, Inc | -101.9 Million USD | 77.589% |
| Check-Cap Ltd. | -19.28 Million USD | -18.406% |
| Twist Bioscience Corporation | -220.83 Million USD | 89.659% |
| Guardant Health, Inc. | -564.72 Million USD | 95.956% |
| Biodesix, Inc. | -41.34 Million USD | 44.761% |
| BioNexus Gene Lab Corp. | -2.59 Million USD | -780.518% |
| Precipio, Inc. | -7.62 Million USD | -199.698% |
| Natera, Inc. | -446.24 Million USD | 94.882% |
| Fulgent Genetics, Inc. | -72.69 Million USD | 68.585% |
| Sera Prognostics, Inc. | -39.82 Million USD | 42.651% |
| 23andMe Holding Co. | -321.35 Million USD | 92.894% |
| OPKO Health, Inc. | -157.02 Million USD | 85.456% |
| Personalis, Inc. | -109.93 Million USD | 79.227% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 76.543% |
| Applied DNA Sciences, Inc. | -10.95 Million USD | -108.494% |
| T2 Biosystems, Inc. | -49.66 Million USD | 54.017% |
| Neogen Corporation | 58.66 Million USD | 138.929% |
| Myriad Genetics, Inc. | -123.7 Million USD | 81.538% |
| ICON Public Limited Company | 956.15 Million USD | 102.388% |
| NeoGenomics, Inc. | -107.73 Million USD | 78.803% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -425.472% |
| MDxHealth SA | -27.32 Million USD | 16.431% |
| Prenetics Global Limited | -52.51 Million USD | 56.512% |
| Illumina, Inc. | -1.06 Billion USD | 97.864% |
| DarioHealth Corp. | -56.18 Million USD | 59.357% |
| ENDRA Life Sciences Inc. | -10.52 Million USD | -117.067% |
| Medpace Holdings, Inc. | 336.82 Million USD | 106.78% |
| Mainz Biomed B.V. | -26.64 Million USD | 14.291% |
| Trinity Biotech plc | -27.04 Million USD | 15.559% |
| Sotera Health Company | 276.69 Million USD | 108.254% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -186.421% |